CureVac

CureVac EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CureVac (CVAC) as of Nov 16, 2026 is 197.09 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -251.83 M EUR — a change of -178.26% (higher).

EBITDA

197.09 MEUR

YoY

-178.26%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CureVac is 2024 197.09 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CureVac was 2023 -251.83 M EUR. It decreases by -178.26% higher compared to the previous year.

The CureVac EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-69.92 M EUR
Jan 1, 2019
-96.70 M EUR
Jan 1, 2020
-128.01 M EUR
Jan 1, 2021
-409.16 M EUR
Jan 1, 2022
-229.16 M EUR
Jan 1, 2023
-251.83 M EUR
Jan 1, 2024
197.09 M EUR
The CureVac EBITDA history
YEAREBITDAYoY
197.09 MEUR-178.26%
-251.83 MEUR+9.89%
-229.16 MEUR-43.99%
-409.16 MEUR+219.64%
-128.01 MEUR+32.38%
-96.70 MEUR+38.29%
-69.92 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CureVac Stock analysis

What does CureVac do? CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CureVac stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CureVac is 197.09 M EUR in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CureVac changed from -251.83 M EUR to 197.09 M EUR, representing a -178.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) CureVac since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CureVac historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CureVac

All Key Metrics — CureVac